title: Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
abstract: BACKGROUND
  Immunotherapy with recombinant interleukin 2 may result in regression of metastatic cancer, particularly malignant melanoma and renal cell carcinoma.
  
  
  METHODS
  We describe a patient who received interleukin 2 immunotherapy for metastatic renal cell carcinoma. After his second course of treatment, he developed a recurrence of pemphigus vulgaris that had been in remission for 10 years.
  
  
  CONCLUSIONS
  Interleukin 2 therapy may be associated with recurrence of an autoimmune disease, perhaps because of its ability to stimulate autoantibody production.
authors.affiliation: Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.
authors.forename: R
authors.initials: R
authors.lastname: Prussick
authors.forename: R T
authors.initials: RT
authors.lastname: Plott
authors.forename: J R
authors.initials: JR
authors.lastname: Stanley
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D010392:Pemphigus / Q000209:etiology* / Q000276:immunology; D012008:Recurrence
chemical_list: D007376:Interleukin-2